IRVINE, Calif. and HERSTAL, Belgium, Jan. 28, 2016 -- MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016:
-
Bank Degroof Petercam Healthcare CEO Seminar on 03 February, Hotel Bloom Brussels, Belgium
-
LSP Biocapital Europe on 09 March, Sofitel Legend Amsterdam, The Grand, The Netherlands
-
European Association of Urology Annual Congress, 11-15 March, Messe Munich International, Germany
-
KBC Securities Benelux Biotech & Healthcare Conference on 22 March, KBC Securities Brussels, Belgium
-
American Urology Association Meeting, 06-10 May, Convention Center of San Diego, California
- FlandersBio Knowledge for Growth on 26 May, ICC Ghent, Belgium
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
|
For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 [email protected] |
|
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR) Consilium Strategic Communications UK: +44 20 3709 5701 [email protected] |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
To access the PDF version, click here http://hugin.info/137314/R/1981850/726160.pdf
HUG#1981850


Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Bill Ackman Eyes New Fund to Bet Against Market Complacency
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 



